Connected Digital Traceability for Cell-Therapy Administration

Abstract

Cell-therapy is at the forefront of precision medicine, offering transformative potential for a range of hematologic and oncologic diseases. However, the complexity of cell sourcing, manufacturing, logistics, and administration necessitates robust traceability to ensure patient safety, regulatory compliance, and therapeutic efficacy. Connected digital traceability systems—integrating electronic health records, manufacturing platforms, and logistics—are emerging as essential tools for the seamless tracking of cell-therapy products. This review synthesizes current evidence on digital traceability frameworks, explores their clinical applications, and discusses their impact on the safe and effective administration of cell-based therapies.

Introduction

The field of cell therapy has witnessed significant advances, with chimeric antigen receptor (CAR) T-cell therapy, hematopoietic stem cell transplantation, and regenerative cellular products entering routine clinical practice. The personalized nature of these therapies and the multistep process from cell collection to patient infusion introduce critical risks of error, contamination, and misidentification. Traditional paper-based or fragmented digital systems are insufficient to address these challenges. Connected digital traceability leverages interoperable platforms and real-time data exchange, providing end-to-end tracking of cell-therapy products, from donor selection to post-infusion monitoring. This article reviews the scientific rationale, clinical implementation, and regulatory framework surrounding connected digital traceability for cell-therapy administration.

Epidemiology / Disease Burden

The global burden of diseases treatable by cell-therapy—including hematological malignancies, genetic disorders, and certain solid tumors—continues to rise. CAR T-cell therapies have gained approval for relapsed/refractory B-cell malignancies, while stem cell transplantation remains a mainstay in leukemia, lymphoma, and some non-malignant hematologic diseases. According to recent global cancer statistics, more than 1.3 million new cases of hematologic malignancies are diagnosed annually. The increasing adoption of cell-based interventions amplifies the need for robust traceability, as the volume and complexity of therapies necessitate advanced systems to safeguard patient outcomes and regulatory compliance.

Pathophysiology

Cell-therapy products are inherently complex, derived from autologous or allogeneic sources, and undergo multiple manipulations—including enrichment, genetic modification, and cryopreservation—before administration. Any deviation or error in handling, identification, or logistics can compromise cell viability, function, and patient safety. Traceability systems must account for the biological variability of cell products, batch-specific attributes, and chain-of-identity from donor to recipient. Mechanism-based digital frameworks use barcoding, radiofrequency identification (RFID), and blockchain technologies to ensure secure, tamper-proof tracking of cellular material throughout the therapeutic process.

Risk Factors

Critical risk factors in cell-therapy administration include mislabeling, cross-contamination, cold-chain failures, and delays in transport or manufacturing. These risks are exacerbated by the individualized nature of therapies and the involvement of multiple stakeholders—collection centers, manufacturing facilities, couriers, and clinical sites. Inadequate traceability can result in adverse events, regulatory breaches, and loss of product integrity. Additionally, the lack of real-time visibility into product status increases the potential for human error, especially when manual documentation is relied upon. Digital traceability systems address these risks by providing automated, standardized, and auditable records across the cell-therapy continuum.

Clinical Features

Clinically, cell-therapy recipients are often immunocompromised and highly vulnerable to adverse outcomes from procedural errors. Accurate patient-product matching, timely infusion, and post-therapy monitoring are crucial for optimizing efficacy and minimizing complications such as graft-versus-host disease (GVHD), infection, or cytokine release syndrome (CRS). Connected traceability platforms support clinicians by offering real-time alerts for deviations, automated verification of chain-of-identity, and integration with clinical decision support systems. These features contribute to improved patient safety and clinical workflow efficiency.

Diagnosis

While diagnosis in cell-therapy refers to identifying eligible patients and monitoring post-infusion outcomes, digital traceability plays a pivotal role in diagnostic accuracy by ensuring that the correct cell product is administered to the intended patient. Digital systems can flag discrepancies, track lot numbers, and document chain-of-custody, thereby minimizing the risk of misadministration. Moreover, integration with laboratory information systems facilitates seamless correlation of product characteristics with patient-specific data, enhancing precision in both diagnosis and therapeutic matching.

Treatment & Management

The management of cell-therapy patients requires meticulous coordination among multidisciplinary teams. Digital traceability facilitates streamlined scheduling, product tracking, and documentation of key process steps, from apheresis collection to infusion. Automated alerts and dashboards enable proactive management of logistics, inventory, and regulatory compliance. In addition, traceability systems support adverse event reporting and pharmacovigilance by providing granular, timestamped records linking patient outcomes with specific product attributes and procedural variables.

Recent Advances / Emerging Therapies

Recent advances in digital traceability include the application of blockchain technology for immutable record-keeping, interoperability with electronic health records (EHRs), and the use of artificial intelligence for predictive analytics. Pilot studies have demonstrated the feasibility of end-to-end digital tracking in CAR T-cell therapy and stem cell transplantation, with enhanced transparency and reduction of manual errors. Regulatory agencies such as the FDA and EMA are increasingly mandating traceability protocols as part of good manufacturing practice (GMP) and advanced therapy medicinal product (ATMP) guidelines. Emerging therapies—including gene-edited cellular products and allogeneic off-the-shelf solutions—further underscore the need for robust digital traceability frameworks to manage complexity and ensure patient safety.

Guideline Recommendations

International guidelines from organizations such as the Foundation for the Accreditation of Cellular Therapy (FACT), the Joint Accreditation Committee (JACIE), and regulatory authorities emphasize the requirement for comprehensive traceability from donor to recipient. Recommendations include the use of validated digital systems, real-time data capture, and standardized identifiers to link clinical, manufacturing, and logistical information. Compliance with guidelines not only mitigates risk but also facilitates quality assurance, pharmacovigilance, and regulatory audits. The integration of digital traceability with clinical workflows is increasingly viewed as a best practice for centers administering advanced cell-based therapies.

Conclusion

Connected digital traceability represents a paradigm shift in the administration of cell-therapy, offering unprecedented transparency, efficiency, and safety. By bridging gaps across the therapeutic continuum, digital platforms minimize the risk of error, enhance regulatory compliance, and improve patient outcomes. As the field evolves, continued investment in interoperable, secure, and user-friendly traceability solutions will be essential to support the expanding landscape of personalized cellular therapies. The integration of digital traceability into clinical practice is no longer optional—it is imperative for the safe and effective delivery of next-generation cell-based interventions.